View Older Stories View More Recent Stories

Dec 18, 2017 07:00AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 15, 2017 07:03AM Sanofi (SNY) and Alnylam (ALNY) Announce FDA Lifted Clinical hold on Fitusiran
Dec 15, 2017 07:01AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 15, 2017 07:01AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 15, 2017 07:00AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 13, 2017 05:49AM Regeneron (REGN) & Sanofi (SNY) Report Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab
Dec 13, 2017 01:02AM Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
Dec 13, 2017 01:02AM Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
Dec 13, 2017 01:01AM Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
Nov 7, 2017 08:26AM Regeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial Program at AHA
Nov 2, 2017 10:46AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Nov 2, 2017 10:45AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Oct 31, 2017 07:14AM Sanofi (SNY) Says Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 31, 2017 06:59AM Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 31, 2017 06:58AM Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 16, 2017 08:06AM Sanofi (SNY), Regeneron (REGN) Phase 2 Study Results for Dupilumab Shows Significant Improvement Versus Placebo
Oct 16, 2017 08:02AM Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 16, 2017 08:01AM Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 16, 2017 08:00AM Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 11, 2017 08:00AM Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Oct 11, 2017 08:00AM Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Oct 5, 2017 12:33PM Sanofi (SNY) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:31PM Regeneron (REGN) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:31PM Sanofi : Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:29PM Sanofi : Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Sep 28, 2017 05:56AM Sanofi (SNY) & Regeneron (REGN) Report Approval of Dupixent (Dupilumab) in European Union to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Sep 28, 2017 01:02AM Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 28, 2017 01:00AM Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 28, 2017 01:00AM Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 20, 2017 07:02AM Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
Sep 20, 2017 07:01AM Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints
Sep 20, 2017 07:00AM Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 07:00AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 06:58AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 18, 2017 05:40AM Sanofi (SNY) & Regeneron Pharmaceuticals (REGN) Report Positive Study Results for Dupixent (Dupilumab)
Sep 16, 2017 02:18AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:18AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:15AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:15AM Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 11, 2017 06:12AM Regeneron (REGN) & Sanofi (SNY) Report Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 11, 2017 01:00AM Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sep 11, 2017 01:00AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 11, 2017 12:58AM Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sep 8, 2017 05:41AM Regeneron (REGN) & Sanofi (SNY) Granted FDA Breakthrough Designation for Cemiplimab (REGN2810), Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 01:00AM Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 01:00AM Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
Aug 25, 2017 08:00AM Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Jul 21, 2017 07:32AM Sanofi (SNY) and Regeneron (REGN) Receive Positive CHMP Opinion for Dupixent to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
View More Recent Stories View Older Stories